Reimbursement landscape
In Europe, reimbursement for remote patient monitoring varies by country, with most countries still developing reimbursement frameworks. Several European countries (Belgium, France, Germany, and the Netherlands) have established reimbursement models for remote patient monitoring, but the processes and conditions can differ significantly from one country to another.
France is the leader in remote patient monitoring from the reimbursement perspective in Europe. Since July 2023, when the new reimbursement framework called the List of Medical Telemonitoring Activities (LATM) replaced the national program for telemedicine “Experiments in Telemedicine for the Improvement of Health Pathways” (ETAPES program). LATM offers a structured reimbursement pathway for remote patient monitoring, expanding beyond the initial conditions covered under ETAPES. Under the LATM framework, two monthly lump-sum payments per patient are reimbursed: a fee for the healthcare provider overseeing the remote monitoring and a fee for the digital medical device operator supplying the necessary technology. Digital medical devices for remote patient monitoring are registered under six categories: digital medical devices for diabetes, cardiac diseases, respiratory diseases, chronic renal failure, oncology, and pain).
In Germany, remote patient monitoring services are reimbursed under the statutory health insurance system through specific codes in the Uniform Evaluation Standard (Einheitlicher Bewertungsmaßstab, EBM): for example, EBM code 03326 for remote monitoring in heart failure.
In the Netherlands, a new payment model for remote patient monitoring was debuted in 2023: telemonitoring is reimbursed as supplementary payment (OZP) under the category “Add-on – other” (code 039133) with a tariff of €185.63 (2025), defined by the Dutch Healthcare Authority (NZa) at the national level and paid on top of the DRG tariff. The procedure code 039133 can be registered and reimbursed once every 120 days. Remote monitoring of patients with multiple (chronic) conditions can be registered per condition, as it concerns different parameters and/or measured values for different medical specialties.
Policy considerations
In general, remote patient monitoring is not eligible for national coverage decisions; it is unlikely to be a subject for approval at the national level by payers or national decision-makers.
Role of HTA
Health Technology Assessment is an important factor influencing the adoption of remote patient monitoring, apart from reimbursement and acceptance by payers / national decision-makers. In most countries, HTA is incorporated into reimbursement decision-making (INAMI/RIZIV in Belgium, HAS in France, “New Methods” framework in Norway). However, in some countries, there are stand-alone HTA organizations whose recommendations can support the adoption of the new remote patient monitoring technologies by healthcare providers (NICE in England or AGENAS in Italy).
For example, in 2024, NICE released diagnostics guidance on algorithm-based systems for remote heart failure monitoring in people with cardiac implantable electronic devices (CIEDs). Two technologies received positive recommendations: HeartLogic and TriageHF, which should be used as options for algorithm-based remote monitoring in people with CIEDs who have heart failure.
Role of Innovation Funding
Innovative payment schemes play an important role in the early adoption of remote patient monitoring technologies in Europe: around 52% of the innovative payment schemes can cover digital technologies, including those used for remote patient monitoring (Early Coverage of Digital Medical Devices (PECAN) in France; Government-co-sponsored studies according to the §137e of the German Social Code Book V in Germany; small-scale experiments for introduction of innovations in the Netherlands). Some of the innovative schemes allow for direct application by the industry (for example, Artificial Intelligence in Health & Care Award and Innovative Devices Access Pathway (IDAP) in England; Early Support for Digital Technologies (PECAN) in France).
In France, a new framework called the “Early Coverage of Digital Medical Devices” (PECAN) was implemented in 2022 to accelerate patient access to innovative digital medical devices (with telemonitoring or therapeutical purposes) in the areas of high unmet need for a one-year non-renewable period. It will facilitate the access of innovative digital medical devices to the market, allowing operators to begin an operational deployment before obtaining regular reimbursement. Since the implementation of the framework, eight digital medical devices were assessed: four digital medical devices for remote patient monitoring (one digital medical device for subacute or chronic low back pain and three digital medical devices for adult patients with cancer undergoing systemic treatment and/or treated with radiotherapy, received favorable opinions of CNEDiMTS with subsequent temporary registration in LATM, whereas four digital medical devices received unfavorable opinions.
Future challenges
Remote patient monitoring is gaining traction in Europe, but challenges related to reimbursement and funding may hinder its widespread adoption and long-term sustainability. There is no established reimbursement for remote patient monitoring in most countries.
Future challenges mostly include establishing a reimbursement framework for remote patient monitoring and expanding existing reimbursement frameworks to novel remote patient monitoring technologies or different indications for its application. HTAs and innovation funding schemes will play an important role in the future adoption of remote patient monitoring.
MTRC has experience with 11 projects related to remote patient monitoring in Europe
News and insights
Get in touch
Contact us to discuss your needs and learn about our services